Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.35 |
| ▸ | HTR2B | P41595 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 8/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9951554 | 1.00 | HTR2A (0.35) | HTR2AHTR2CHTR2BMAOBPTGS2 | |
| SCHEMBL10188806 | 0.83 | PTGS2 (0.35) | HTR2AHTR2CHTR2BMAOBPTGS2 | |
| SCHEMBL10241538 | 0.77 | PTGS2 (0.37) | HTR2AHTR2CHTR2BMAOBPTGS2 | |
| SCHEMBL9950042 | 0.74 | CYP3A4 (0.36) | HTR2AHTR2CHTR2BMAOB | |
| SCHEMBL9950072 | 0.70 | — | — | |
| SCHEMBL9950074 | 0.70 | — | — | |
| SCHEMBL2118674 | 0.70 | HCRTR1 (0.38) | — | |
| SCHEMBL2118678 | 0.70 | HCRTR1 (0.38) | — | |
| SCHEMBL2118681 | 0.70 | HCRTR1 (0.38) | — | |
| SCHEMBL2610462 | 0.69 | LMNA (0.35) | HTR2AHTR2CHTR2BMAOBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HTR2A 133/4885HTR2C 152/4885HTR2B 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.